Clinical trial • Phase I • Neurology
MK-4605 for Dementia
Phase I trial of MK-4605 for Dementia. 16 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Dementia
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 30-03-2026
- First CTIS Authorization Date
- 06-05-2026
Trial design
Phase I trial across 1 site in Belgium.
- Target Sample Size
- 16
- Trial Duration For Participant
- 99
Eligibility
Recruits 16 No vulnerable populations selected (isVulnerablePopulationSelected=false)..
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected=false).
Recruitment
- Planned Sample Size
- 16
- Recruitment Window Months
- 3
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 16
Belgium
- Earliest CTIS Part Ii Submission Date
- 22-04-2026
- Latest Decision Or Authorization Date
- 06-05-2026
- Processing Time Days
- 14
- Number Of Sites
- 1
- Number Of Participants
- 16
Sites
- Site Name
- Universitair Ziekenhuis Gent
- Department Name
- DRUG
- Contact Person Name
- Griet Van Lancker
- Contact Person Email
- griet.vanlancker@uzgent.be
- Number Of Participants
- 16
Sponsor
Primary sponsor
- Full Name
- Merck Sharp & Dohme LLC
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- MK-4605
Related trials
Other published trials that may interest you.
- OCRELIZUMAB for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Secondary progressive multiple sclerosis (active)
- CENOBAMATE for Partial-onset (focal) seizures
- Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis
- Clinical trial in Parkinson's disease
- Tenecteplase for Acute ischaemic stroke due to basilar artery occlusion | Posterior circulation ischaemic stroke